| Primary information |
|---|
| PRRID | PRRID_0637 |
| Ligand Name | Lipopolysaccharide (LPS) |
| Source | Gram-negative bacteria |
| Sequence of ligand | CCCCCCCCCCCCCC(=O)OC(CCCCCCCCCCC)CC(=O)OC1C(C(OC(C1OP(=O)(O)O)CO)OCC2C(C(C(C(O2)OP(=O)(O)O)NC(=O)CC(CCCCCCCCCCC)O)OC(=O)CC(CCCCCCCCCCC)O)O)NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC |
| Length | NA |
| Type | Lipopolysaccharide (LPS) |
| Occurence | Natural |
| Role of Ligand | LPS treatment of fibroblasts induced IκBα degradation, enhanced NFκB promoter activity and increased collagen contraction |
| Name of receptor | Toll-like receptor 4 (TLR4) |
| Type of receptor | Toll-like receptor (TLR) |
| Source | Human |
| Localization | Intestinal Fibroblasts |
| Domain | Leucine-rich Repeat (LRR) Domain |
| Sequence of Receptor | O00206.fasta |
| Swiss prot ID | O00206 |
| Length Of Receptor | 839 |
| Function | It induces collagen contraction and reduces the expression of the TGF-β1 inhibitor, smad-7 which results in intestinal injury following injury. |
| Assay used | Luciferase assay |
| PMID | 20632282 |
| Year of Publication | 2010 |
| Pubchem assay | Pubchem Assay |
| Primary information |
|---|
| PRRID | PRRID_0637 |
| Ligand Name | Lipopolysaccharide (LPS) |
| Source | Gram-negative bacteria |
| Sequence of ligand | CCCCCCCCCCCCCC(=O)OC(CCCCCCCCCCC)CC(=O)OC1C(C(OC(C1OP(=O)(O)O)CO)OCC2C(C(C(C(O2)OP(=O)(O)O)NC(=O)CC(CCCCCCCCCCC)O)OC(=O)CC(CCCCCCCCCCC)O)O)NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC |
| Length | NA |
| Type | Lipopolysaccharide (LPS) |
| Occurence | Natural |
| Role of Ligand | LPS treatment of fibroblasts induced IκBα degradation, enhanced NFκB promoter activity and increased collagen contraction |
| Name of receptor | Toll-like receptor 4 (TLR4) |
| Type of receptor | Toll-like receptor (TLR) |
| Source | Human |
| Localization | Intestinal Fibroblasts |
| Domain | Leucine-rich Repeat (LRR) Domain |
| Sequence of Receptor | O00206.fasta |
| Swiss prot ID | O00206 |
| Length Of Receptor | 839 |
| Function | It induces collagen contraction and reduces the expression of the TGF-β1 inhibitor, smad-7 which results in intestinal injury following injury. |
| Assay used | Luciferase assay |
| PMID | 20632282 |
| Year of Publication | 2010 |
| Pubchem assay | Pubchem Assay |